Vale SA
VALE
D.R. Horton
DHI
Taylor Morrison Home
TMHC
Petroleo Brasileiro SA Petrobras
PBR
Ecopetrol
EC
US Stock MarketDetailed Quotes
QNRX Quoin Pharmaceuticals
- 0.2952
- -0.0098-3.21%
Close Mar 18 16:00 ET
6.08MMarket Cap-0.15P/E (TTM)
0.3048High0.2901Low502.53KVolume0.3000Open0.3050Pre Close149.59KTurnover2.60%Turnover RatioLossP/E (Static)20.59MShares1.570052wk High0.66P/B5.71MFloat Cap0.270352wk Low--Dividend TTM19.35MShs Float40500.0000Historical High--Div YieldTTM4.82%Amplitude0.2703Historical Low0.2970Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Quoin Pharmaceuticals Stock Forum
Quoin's Netherton Treatment Shows Dramatic Results, Secures FDA Green Light
Can Quoin's New Rapamycin Patents Transform Treatment for These Orphan Diseases?
just keep holding still early days. all year long if we have to I'll never sell at a loss
Quoin Pharmaceuticals Ltd. (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. Dramatic improvement was observed in the patient’s disease state with clear visual evidence of skin healing observed after just two weeks of whole-body application of QRX003.
Both key clinic...
No comment yet